Badía J I, Wild R, Barrena N, Mayerson D, Duarte I
Departamento de Obstetricia y Ginecología, Pontificia Universidad Católica de Chile.
Rev Chil Obstet Ginecol. 1991;56(6):393-402; discussion 402-3.
We present the results on the treatment of 43 patients with epithelial ovarian cancer excluding borderline tumours. Nine cases were FIGO Stage I, 4 FIGO Stage II, 24 FIGO Stage III and 6 FIGO Stage IV. The protocol consists in cytoreductive surgery followed by chemotherapy for Stages I, III, and IV, mainly using cisplatin + cyclophosphamide (PC) or cisplatin + adriamycin + cyclophosphamide (PAC). We used pelvis and whole abdomen radiotherapy for patients on Stage II. The follow up was between 26 and 76 months. The undifferentiated tumours had bad prognosis in Stage I, instead of receiving chemotherapy. Radiotherapy for patients on Stage II reached satisfactory local regional disease control but with late recurrences. On Stage III, size of residual tumour less than 2 cm on primary surgery was of good prognosis (60% 44 months survival). The addition of adriamycin to PC seems to be of no benefit in long term results. The five year actuarial survival was 44% for FIGO Stage I, 75% for FIGO Stage II, 16% for FIGO Stage III and 0% for FIGO Stage IV. These results don't differ significantly from similar protocols.
我们展示了43例上皮性卵巢癌（不包括交界性肿瘤）患者的治疗结果。9例为国际妇产科联盟（FIGO）Ⅰ期，4例为FIGOⅡ期，24例为FIGOⅢ期，6例为FIGOⅣ期。治疗方案包括对Ⅰ期、Ⅲ期和Ⅳ期患者先进行肿瘤细胞减灭术，然后进行化疗，主要使用顺铂+环磷酰胺（PC）或顺铂+阿霉素+环磷酰胺（PAC）。对于Ⅱ期患者，我们采用盆腔和全腹放疗。随访时间为26至76个月。Ⅰ期未分化肿瘤预后不良，未接受化疗。Ⅱ期患者放疗达到了令人满意的局部区域疾病控制，但复发较晚。在Ⅲ期，初次手术时残留肿瘤大小小于2 cm预后良好（44个月生存率为60%）。在PC方案中添加阿霉素似乎对长期结果没有益处。FIGOⅠ期患者的五年精算生存率为44%，FIGOⅡ期为75%，FIGOⅢ期为16%，FIGOⅣ期为0%。这些结果与类似方案没有显著差异。
